✨ Free AI Report
Xvivo Perfusion AB: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Xvivo Perfusion AB
Company Research

Xvivo Perfusion AB: Business Overview, Financials & Competitive Analysis

Founded in 1998, XVIVO is the only MedTech company dedicated to extending the life of all major organs. The company offers machine perfusion technologies for kidneys, livers, and lungs, a solution for cold static stor...

Analyst-debate audio for Xvivo Perfusion AB

AskCyborg analysts argue the bull and bear cases for Xvivo Perfusion AB across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Orphan medtech company with monopoly-like market positions in critical niche (organ transplant preservation) with international...

Read the full analyst-debate transcript →
Industry Medical Technology - Organ Transplant Preservation & Perfusion Systems
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Xvivo Perfusion AB Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Xvivo Perfusion AB Overview

Pro stress-test →

Founded in 1998, XVIVO is the only MedTech company dedicated to extending the life of all major organs. The company offers machine perfusion technologies for kidneys, livers, and lungs, a solution for cold static storage of lungs, as well as organ recovery and perfusion services. XVIVO is trusted by more than 90% of all transplantation clinics, and the standard treatment in lung transplants.

Strategic Profile

Pro stress-test →

In lung transplantation, XVIVO markets PERFADEX Plus for cold preservation and XPS with STEEN Solution for machine perfusion, where it is the global leader. For liver transplantation, XVIVO markets Liver Assist, the leading perfusion technology in Europe. XVIVO aims to be the fastest growing company in kidney perfusion.

Competitive Landscape

Pro stress-test →

Boston Scientific, ResMed, Medtronic, Avinger, and Angiodynamics are competitors in the broader medical device space, though XVIVO's specialized focus on organ preservation gives it a niche market advantage with limited direct competition in its core segments. The company's market dominance in lung preservation (90% market share) and leadership in liver perfusion create high barriers to entry.

Industry Context

Xvivo Perfusion AB operates in Medical Technology - Organ Transplant Preservation & Perfusion Systems.

Key facts

Founded: 1998 · Headquarters: Mölndal, Sweden · Employees: 200 · Revenue: $79.9M · Market cap: $579M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Xvivo Perfusion AB.

  • PERFADEX® Plus is a patented solution for flushing and static cold storage of lungs, used by more than 90% of transplantation clinics globally
  • Liver Assist, celebrating its 25th anniversary in 2024, is the most scientifically validated liver perfusion technology, featured in multiple randomized control trials, and enables extended liver perfusion times of up to 20 hours
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2025Heart transplant preservation technology approaching CE marking for European launch
  • 2024Liver Assist clinically validated in Lancet study demonstrating 20-hour perfusion capability
  • +1 moreTrack every material event for Xvivo Perfusion AB as it happens. Explore monitoring →
Get alerted when Xvivo Perfusion AB has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Organ Preservation TechnologiesNormothermic organ perfusion systems→Surgical DevicesDiversified medical device manufacturer→Patient MonitoringCloud-connected medical devices→

Compare Xvivo Perfusion AB with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Xvivo Perfusion AB operates in Medical Technology - Organ Transplant Preservation & Perfusion Systems. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Technology - Organ Transplant Preservation & Perfusion Systems research →
NEW · MCP server

Ask your AI assistant about Xvivo Perfusion AB

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Xvivo Perfusion AB and its top competitor on Cyborg Score”
“What did Xvivo Perfusion AB do this quarter?”
“Is Xvivo Perfusion AB a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Xvivo Perfusion AB do?+
Founded in 1998, XVIVO is the only MedTech company dedicated to extending the life of all major organs. The company offers machine perfusion technologies for kidneys, livers, and lungs, a solution for cold static stor...
What is Xvivo Perfusion AB's Cyborg Score?+
Xvivo Perfusion AB has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Xvivo Perfusion AB's main competitors?+
Named competitors include Organ Preservation Technologies, Surgical Devices, Patient Monitoring. The full competitive landscape is in the AskCyborg report.
How can I get the full Xvivo Perfusion AB research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Xvivo Perfusion AB research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Xvivo Perfusion AB over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.